Las Vegas cannabis company, GB Sciences has announced today that they have obtained an exclusive license to develop, manufacture, and sell cannabis-infused oral thin films for medicinal use in Nevada and Louisiana.
Some of the oral thin films will be infused with either tetrahydrocannabinol (THC) or cannabidiol (CBD) while others will contain a defined-ratio mix of the two cannabinoids with additional proprietary active ingredients developed for the treatment of chronic pain, inflammation, and other conditions.
“Oral thin films are very effective, easy to use, and have many advantages over other delivery systems on the market,” says SB Sciences Director and CSO, Dr. Andrea Small-Howard. “The active ingredients in cannabis, such as cannabinoids and terpenes, are more bioavailable via oral thin films because they’re absorbed directly by the cells in the mouth, then pass into the bloodstream.”
“That means quicker delivery and more complete dosing, without some of the negatives associated with edibles,” she says.
GB Sciences CEO, John Poss, says that their new license will allow them to get their products to patients in Nevada and Louisiana right away, providing them a new way to consume precisely-dosed medical cannabis products without potential drawbacks of other delivery methods.
The company’s President, John Davis, says that the incorporation of oral thin film technology is consistent with their approach of putting patients first by providing them with product options and effective delivery systems.
